Edge-GPU breast tomosynthesis box market seen growing to $0.99B by 2030

The Business Research Company says the edge-GPU breast tomosynthesis box market will rise from $0.53 billion in 2025 to $0.61 billion in 2026, then reach $0.99 billion by 2030. North America led the market in 2025, while Asia-Pacific is projected to be the fastest-growing region as breast cancer screening demand and AI-enabled imaging expand.

Why it matters: - The market supports faster, higher-resolution 3D breast imaging for cancer screening and diagnosis. - Rising breast cancer incidence is increasing demand for imaging systems that can improve early detection and treatment planning. - The technology combines edge computing and GPU acceleration, which can reduce latency and speed up clinical workflows.

What happened: - The Business Research Company released a market intelligence report on the edge-GPU breast tomosynthesis box market. - The report estimates the market will grow from $0.53 billion in 2025 to $0.61 billion in 2026. - The report projects the market will reach $0.99 billion by 2030. - The report places 2025 market leadership in North America. - The report identifies Asia-Pacific as the fastest-growing regional market over the next several years.

The details: - The report ties 2025-2026 growth to adoption of breast tomosynthesis technology, advances in edge-GPU computing, rising demand for high-resolution 3D imaging, expansion of breast cancer screening programs, and better imaging detectors. - The report expects a 13.3% compound annual growth rate from 2025 to 2026. - The report forecasts a 13.0% compound annual growth rate through 2030. - The report says future growth will come from AI-powered diagnostic tools, portable screening devices, cloud-based imaging connectivity, faster image processing, and wider use in clinical and research settings. - The report highlights real-time 3D imaging, GPU-accelerated data processing, enhanced diagnostic precision, AI-driven image analysis, and portable imaging technologies as key trends. - The technology processes imaging data at the edge, which reduces dependence on centralized servers. - Typical system components include GPU-powered workstations, specialized imaging detectors, and software designed to improve diagnostic accuracy. - The system is used in healthcare settings to support early detection and detailed evaluation of breast abnormalities. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. - The 2026 report package adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, plus updated graphics and tables. - The report includes a free sample and the full market report online: free sample and full report.

Between the lines: - The market story is less about a single device and more about the convergence of imaging, edge computing, and AI in breast cancer workflows. - North America's lead suggests established screening infrastructure, while Asia-Pacific's growth outlook points to broader adoption potential in expanding healthcare markets. - The report frames portability and cloud connectivity as signs that imaging systems are moving beyond fixed, centralized workflows. - According to the American Cancer Society in July 2024, about 310,720 new invasive breast cancer cases were expected in U.S. women in 2024, with 16% in women under 50, plus about 56,500 cases of ductal carcinoma in situ.

What's next: - The market is expected to keep expanding through 2030 as AI-assisted diagnostics and portable imaging gain traction. - Regional competition will likely intensify as Asia-Pacific adoption accelerates and vendors push faster processing and better diagnostic precision. - The report's added analytics tools suggest buyers and investors will have more data to compare opportunities across segments and regions.

The bottom line: - Edge-GPU breast tomosynthesis boxes are moving from niche imaging tools to a broader platform for faster, more accurate breast cancer screening.